Key Highlights
- 510(k) clearance grants Air Next Spirometer in-home use for comprehensive spirometry.
- Enables real-time lung health monitoring, reducing hospital visits for COPD, Asthma, and ALS patients.
- Supports ATS 2019-compliant spirometry, expanding clinical trial capabilities across the US and Europe.
Source: Business Wire
Notable Quotes
- “Air Next is capable of providing our care team with high-quality lung measurements from the comfort of our patients’ homes,” – Eric Harker, MD MPH MBA, Chief Medical Officer at NuvoAir
- “Air Next brings the reliability of in-clinic spirometry right to our patients’ hands,” – Furat Shawki, General Manager of Clinical Trials at NuvoAir
SoH's Take
The 510(k) clearance of NuvoAir’s Air Next Spirometer marks a pivotal advancement in pulmonary healthcare. This breakthrough not only signifies a leap in patient-centric care but also heralds a new era of efficiency and precision in chronic lung condition management. By enabling at-home, high-quality lung monitoring, NuvoAir is setting a new standard in proactive care, ensuring that patients with critical respiratory conditions receive timely interventions, thus minimizing the need for hospital admissions. Moreover, the integration of ATS 2019-compliant spirometry into clinical trials signifies an innovative stride in respiratory research, broadening the horizon for future advancements in cardiopulmonary healthcare solutions. As NuvoAir continues to blend cutting-edge technology with patient-focused care, its role in transforming the landscape of respiratory health management becomes increasingly indispensable.
